Pozen said it will initiate a toxicity trial of its migraine treatment Trexima on human subjects in an attempt to ease FDA concerns and obtain regulatory approval for the drug. The biotech firm also has sent additional safety data to the FDA in response to an approvable letter the agency issued for Trexima.

Related Summaries